PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment
The first arm of the phase 2 PROSPECT study evaluating tirabrutinib for the treatment of relapsed/refractory primary central nervous system lymphoma has finished enrolling patients.